

Salmaan Keshavjee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5730162/publications.pdf>

Version: 2024-02-01

87
papers

5,162
citations

186209

28
h-index

91828

69
g-index

89
all docs

89
docs citations

89
times ranked

5097
citing authors

#	ARTICLE	IF	CITATIONS
1	A role for community-level socioeconomic indicators in targeting tuberculosis screening interventions. <i>Scientific Reports</i> , 2022, 12, 781.	1.6	2
2	Mapping local hot spots with routine tuberculosis data: A pragmatic approach to identify spatial variability. <i>PLoS ONE</i> , 2022, 17, e0265826.	1.1	3
3	Geographic accessibility to health facilities predicts uptake of community-based tuberculosis screening in an urban setting. <i>International Journal of Infectious Diseases</i> , 2022, 120, 125-131.	1.5	6
4	Low Body Mass Index at Treatment Initiation and Rifampicin-Resistant Tuberculosis Treatment Outcomes: An Individual Participant Data Meta-Analysis. <i>Clinical Infectious Diseases</i> , 2022, 75, 2201-2210.	2.9	5
5	Risk Factors for Adverse Events in Household Contacts Prescribed Preventive Treatment for Drug-resistant Tuberculosis Exposure. <i>Clinical Infectious Diseases</i> , 2021, 72, 1709-1715.	2.9	8
6	Impact of latent tuberculosis infection on health and wellbeing: a systematic review and meta-analysis. <i>European Respiratory Review</i> , 2021, 30, 200260.	3.0	9
7	Social Theories for Global Health Research and Practice. , 2021, , 1127-1143.		2
8	Closing delivery gaps in the treatment of tuberculosis infection: Lessons from implementation research in Peru. <i>PLoS ONE</i> , 2021, 16, e0247411.	1.1	5
9	Effectiveness of Preventive Therapy for Persons Exposed at Home to Drug-Resistant Tuberculosis, Karachi, Pakistan. <i>Emerging Infectious Diseases</i> , 2021, 27, 805-812.	2.0	13
10	The need for protecting and enhancing TB health policies and services for forcibly displaced and migrant populations during the ongoing COVID-19 pandemic. <i>International Journal of Infectious Diseases</i> , 2021, 113, S22-S27.	1.5	5
11	Vaccination plus Decarceration “Stopping Covid-19 in Jails and Prisons. <i>New England Journal of Medicine</i> , 2021, 384, 1583-1585.	13.9	46
12	Safety and feasibility of 1 month of daily rifapentine plus isoniazid to prevent tuberculosis in children and adolescents: a prospective cohort study. <i>The Lancet Child and Adolescent Health</i> , 2021, 5, 350-356.	2.7	19
13	Improving community health-care screenings with smartphone-based AI technologies. <i>The Lancet Digital Health</i> , 2021, 3, e280-e282.	5.9	9
14	Identifying barriers and facilitators to implementation of community-based tuberculosis active case finding with mobile X-ray units in Lima, Peru: a RE-AIM evaluation. <i>BMJ Open</i> , 2021, 11, e050314.	0.8	15
15	Siamit: A Novel Academic Tribal Health Partnership in Northwest Alaska. <i>Academic Medicine</i> , 2021, 96, 1560-1563.	0.8	5
16	Strengthening healthcare delivery with remote patient monitoring in the time of COVID-19. <i>BMJ Health and Care Informatics</i> , 2021, 28, e100302.	1.4	14
17	Toward patient-centered tuberculosis preventive treatment: preferences for regimens and formulations in Lima, Peru. <i>BMC Public Health</i> , 2021, 21, 121.	1.2	10
18	Cost of Delivering 12-Dose Isoniazid and Rifapentine Versus 6 Months of Isoniazid for Tuberculosis Infection in a High-Burden Setting. <i>Clinical Infectious Diseases</i> , 2021, 73, e1135-e1141.	2.9	11

#	ARTICLE	IF	CITATIONS
19	Social Theories for Global Health Research and Practice. , 2021, , 1-18.		0
20	COVID-19 and Tuberculosisâ€”A Global Tale of Hubris and Lessons Unlearned?. <i>Frontiers in Medicine</i> , 2021, 8, 799640.	1.2	1
21	Tuberculosis Preventive Therapy for Individuals Exposed to Drug-resistant Tuberculosis: Feasibility and Safety of a Community-based Delivery of Fluoroquinolone-containing Preventive Regimen. <i>Clinical Infectious Diseases</i> , 2020, 70, 1958-1965.	2.9	16
22	The impact of the COVID-19 epidemic on tuberculosis control in China. <i>The Lancet Regional Health - Western Pacific</i> , 2020, 3, 100032.	1.3	54
23	Risk-benefit analysis of tuberculosis infection testing for household contact management in high-burden countries: a mathematical modelling study. <i>The Lancet Global Health</i> , 2020, 8, e672-e680.	2.9	11
24	Trends, patterns and health consequences of multimorbidity among South Korea adults: Analysis of nationally representative survey data 2007-2016. <i>Journal of Global Health</i> , 2020, 10, 020426.	1.2	19
25	Supporting a Comprehensive International Approach to Global Tuberculosis Eradication Is the Right Thing to Do. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 1499-1500.	2.5	0
26	COVID-19 reveals weak health systems by design: Why we must re-make global health in this historic moment. <i>Global Public Health</i> , 2020, 15, 1083-1089.	1.0	103
27	Tuberculosis Epidemic ControlA Comprehensive Strategy to Drive Down Tuberculosis. , 2020, , 401-411.		5
28	Health systems performance in managing tuberculosis: analysis of tuberculosis care cascades among high-burden and non-high-burden countries. <i>Journal of Global Health</i> , 2019, 9, 010423.	1.2	21
29	Cost-effectiveness of scaling up of hepatitis C screening and treatment: a modelling study in South Korea. <i>BMJ Global Health</i> , 2019, 4, e001441.	2.0	5
30	The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis. <i>Lancet Respiratory Medicine</i> , 2019, 7, 820-826.	5.2	92
31	Tuberculosis household accompaniment to improve the contact management cascade: A prospective cohort study. <i>PLoS ONE</i> , 2019, 14, e0217104.	1.1	19
32	Video-observed therapy for tuberculosis: strengthening care. <i>Lancet, The</i> , 2019, 393, 1180-1181.	6.3	5
33	Moving toward Tuberculosis Elimination. Critical Issues for Research in Diagnostics and Therapeutics for Tuberculosis Infection. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 564-571.	2.5	20
34	Blind Spot. , 2019, , .		62
35	4. Health for All? Competing Theories and Geopolitics. , 2019, , 74-110.		5
36	18. Structural Violence and Clinical Medicine (2006). , 2019, , 376-392.		0

#	ARTICLE	IF	CITATIONS
37	Turning Off the Tap: Using the FAST Approach to Stop the Spread of Drug-Resistant Tuberculosis in the Russian Federation. <i>Journal of Infectious Diseases</i> , 2018, 218, 654-658.	1.9	12
38	Use of predicted vital status to improve survival analysis of multidrug-resistant tuberculosis cohorts. <i>BMC Medical Research Methodology</i> , 2018, 18, 166.	1.4	3
39	Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. <i>Lancet, The</i> , 2018, 392, 821-834.	6.3	452
40	Using the Consolidated Framework for Implementation Research to implement and evaluate national surgical planning. <i>BMJ Global Health</i> , 2017, 2, e000269.	2.0	23
41	Aggressive Regimens Reduce Risk of Recurrence After Successful Treatment of MDR-TB. <i>Clinical Infectious Diseases</i> , 2016, 63, 214-220.	2.9	19
42	Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method. <i>European Respiratory Journal</i> , 2016, 48, 1160-1170.	3.1	27
43	Surgery as an Adjunctive Treatment for Multidrug-Resistant Tuberculosis: An Individual Patient Data Metaanalysis. <i>Clinical Infectious Diseases</i> , 2016, 62, 887-895.	2.9	64
44	Double Standards in Global Health: Medicine, Human Rights Law and Multidrug-Resistant TB Treatment Policy. <i>Health and Human Rights</i> , 2016, 18, 85-102.	1.3	13
45	Global and Regional Burden of Isoniazid-Resistant Tuberculosis. <i>Pediatrics</i> , 2015, 136, e50-e59.	1.0	39
46	Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2015, 5, a017863.	2.9	372
47	Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies. <i>Lancet Respiratory Medicine</i> , 2015, 3, 201-209.	5.2	116
48	Stopping the body count: a comprehensive approach to move towards zero tuberculosis deaths. <i>Lancet, The</i> , 2015, 386, e46-e47.	6.3	48
49	Turning off the tap: stopping tuberculosis transmission through active case-finding and prompt effective treatment. <i>Lancet, The</i> , 2015, 386, 2334-2343.	6.3	136
50	HIV-Care Outcome in Saudi Arabia; a Longitudinal Cohort. <i>Journal of AIDS & Clinical Research</i> , 2014, 05, .	0.5	10
51	Shifting Gears to Control Drug-Resistant Tuberculosis. <i>Clinical Infectious Diseases</i> , 2014, 59, 908-910.	2.9	1
52	Global Financing and Long-Term Technical Assistance for Multidrug-Resistant Tuberculosis: Scaling Up Access to Treatment. <i>PLoS Medicine</i> , 2014, 11, e1001738.	3.9	9
53	Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies. <i>BMJ Open</i> , 2014, 4, e004143.	0.8	67
54	Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates. <i>Lancet, The</i> , 2014, 383, 1572-1579.	6.3	256

#	ARTICLE	IF	CITATIONS
55	Drug-resistant TB can be contained. <i>Nature</i> , 2014, 506, 295-295.	13.7	4
56	Improving Outcomes for Multidrug-Resistant Tuberculosis: Aggressive Regimens Prevent Treatment Failure and Death. <i>Clinical Infectious Diseases</i> , 2014, 59, 9-15.	2.9	45
57	History of Tuberculosis and Drug Resistance. <i>New England Journal of Medicine</i> , 2013, 368, 88-90.	13.9	30
58	Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. <i>European Respiratory Journal</i> , 2013, 42, 169-179.	3.1	226
59	Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. <i>European Respiratory Journal</i> , 2013, 42, 156-168.	3.1	346
60	Aspiring to Zero Tuberculosis Deaths among Southern Africa's Miners: Is There a Way Forward?. <i>International Journal of Health Services</i> , 2013, 43, 651-664.	1.2	18
61	Isoniazid-resistant Tuberculosis in Children. <i>Pediatric Infectious Disease Journal</i> , 2013, 32, e217-e226.	1.1	34
62	Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients. <i>PLoS Medicine</i> , 2012, 9, e1001300.	3.9	430
63	Eliminating the category of retreatment regimen from national tuberculosis programme guidelines: the Georgian experience. <i>Bulletin of the World Health Organization</i> , 2012, 90, 63-66.	1.5	22
64	Tuberculosis, Drug Resistance, and the History of Modern Medicine. <i>New England Journal of Medicine</i> , 2012, 367, 931-936.	13.9	220
65	Eradication: ridding the world of diseases forever?. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 372.	4.6	0
66	Engaging the private sector to increase tuberculosis case detection: an impact evaluation study. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 608-616.	4.6	122
67	Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projects. <i>Tuberculosis</i> , 2012, 92, 397-403.	0.8	123
68	Cost and cost-effectiveness of multidrug-resistant tuberculosis treatment in Estonia and Russia. <i>European Respiratory Journal</i> , 2012, 40, 133-142.	3.1	42
69	Outcomes of Comprehensive Care for Children Empirically Treated for Multidrug-Resistant Tuberculosis in a Setting of High HIV Prevalence. <i>PLoS ONE</i> , 2012, 7, e37114.	1.1	27
70	Rational use of moxifloxacin for tuberculosis treatment. <i>Lancet Infectious Diseases</i> , The, 2011, 11, 259-260.	4.6	11
71	Time for zero deaths from tuberculosis. <i>Lancet</i> , The, 2011, 378, 1449-1450.	6.3	9
72	In reply to "Universal access for MDR-TB limited without the involvement of the private sector" [Correspondence]. <i>International Journal of Tuberculosis and Lung Disease</i> , 2011, 15, 851-852.	0.6	0

#	ARTICLE	IF	CITATIONS
73	Picking Up the Pace – Scale-Up of MDR Tuberculosis Treatment Programs. <i>New England Journal of Medicine</i> , 2010, 363, 1781-1784.	13.9	57
74	Development of Extensively Drug-resistant Tuberculosis during Multidrug-resistant Tuberculosis Treatment. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 426-432.	2.5	82
75	Time for a bold new vision at the Stop TB Partnership. <i>Lancet, The</i> , 2010, 376, 1283-1284.	6.3	3
76	Early Outcomes of MDR-TB Treatment in a High HIV-Prevalence Setting in Southern Africa. <i>PLoS ONE</i> , 2009, 4, e7186.	1.1	104
77	Treatment of extensively drug-resistant tuberculosis – Authors' reply. <i>Lancet, The</i> , 2009, 373, 27-28.	6.3	2
78	Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study. <i>Lancet, The</i> , 2008, 372, 1403-1409.	6.3	150
79	Aviation and the Delivery of Medical Care in Remote Regions: The Lesotho HIV Experience. <i>Aviation, Space, and Environmental Medicine</i> , 2008, 79, 136-138.	0.6	5
80	Extensively Drug-Resistant Tuberculosis, Lesotho. <i>Emerging Infectious Diseases</i> , 2008, 14, 992-993.	2.0	10
81	Building Capacity for Multidrug-Resistant Tuberculosis Treatment: Health Systems Strengthening in Lesotho. <i>Innovations</i> , 2007, 2, 87-106.	3.4	3
82	Bleeding Babies in Badakhshan. <i>Medical Anthropology Quarterly</i> , 2006, 20, 72-93.	0.7	4
83	Structural Violence and Clinical Medicine. <i>PLoS Medicine</i> , 2006, 3, e449.	3.9	698
84	Medicine and money: the ethical transformation of medical practice. <i>Medical Education</i> , 2004, 38, 271-275.	1.1	7
85	Medicine betrayed: hemophilia patients and HIV in the US. <i>Social Science and Medicine</i> , 2001, 53, 1081-1094.	1.8	17
86	Disintegrating Health Services and Resurgent Tuberculosis in Post-Soviet Tajikistan: An Example of Structural Violence. <i>JAMA - Journal of the American Medical Association</i> , 2000, 283, 1201.	3.8	19
87	SENSITIVITY OF VARIOUS CASE DETECTION ALGORITHMS FOR COMMUNITY-BASED TB SCREENING. <i>Clinical Infectious Diseases</i> , 0, , .	2.9	0